<DOC>
	<DOCNO>NCT02025907</DOCNO>
	<brief_summary>The purpose study assess effect canagliflozin ( JNJ-28431754 ) compare placebo treatment participant Type 2 Diabetes Mellitus ( T2DM ) , inadequate glycemic control maximally near-maximally effective dos metformin sitagliptin .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Addition Canagliflozin Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control Metformin Sitagliptin</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled ( inactive substance compare study drug , test whether study drug real effect ) , multicenter study efficacy , safety , tolerability canagliflozin participant T2DM , inadequate glycemic ( blood sugar ) control maximally near-maximally effective dos metformin &gt; =1500 mg/day sitagliptin 100 mg/day . Approximately 200 participant randomly assign 1 2 treatment group 1:1 ratio 26 week . During study participant also provide diet exercise counseling ( standardized non-pharmacological therapy ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Must diagnosis type 2 diabetes mellitus Must screen HbA1c &gt; =7.5 % &lt; =10.5 % Must metformin &gt; =1500 mg/day sitagliptin 100 mg/day ( equivalent fix dose combination ) stable dose least 12 week screen History diabetic ketoacidosis T1DM , hereditary glucosegalactose malabsorption primary renal glycosuria A myocardial infarction , unstable angina , revascularization procedure cerebrovascular accident within 12 week screen eGFR &lt; 60 ml/min/1.73m2 , serum creatinine &gt; =1.4 mg/dL men &gt; =1.3 mg/dL woman Known significant liver disease ( eg , acute hepatitis , chronic active hepatitis , cirrhosis ) Major surgery ( ie , require general anesthesia ) within 12 week screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Hemoglobin A1c</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>T2DM</keyword>
	<keyword>JNJ-28431754</keyword>
</DOC>